| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3be2429bd1a83fd492acffa31808839c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2020-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3778f739fa3fe8eb786f25a16339e47f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6f5f5e4e666216e3097ac1d03f604e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_243925e72f165f6a01a75a78ffd43ec4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01fbf56b5b2c25903aeca2179f1f3deb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b82b9d2aa3be51083bd29fe4083d8a0 |
| publicationDate |
2020-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CO-2020001792-A2 |
| titleOfInvention |
Pharmaceutical combinations |
| abstract |
The invention relates to pharmaceutical combinations comprising antibodies against BST1 (ADP-ribosyl cyclase 2) together with a cytidine analog or one of its pharmaceutically acceptable salts, and methods for the treatment of diseases such as cancers mediated by the expression / activity of BST1 (ADP-ribosyl cyclase 2) and / or associated with the abnormal expression / activity of BST1. |
| priorityDate |
2017-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |